If you've built any part of your performance stack around peptides, the regulatory ground just shifted under you. The FDA's recent removal of several peptides from its Category 2 bulk drug substances list has created a landscape where compounds you may have been using for months. or years. are now in legal limbo. Here's what actually changed, what it means for your health, and how to figure out where you stand right now.
What the Category 2 List Actually Means
The FDA's bulk drug substance categories exist to govern what compounding pharmacies can legally use in their preparations. Category 1 compounds have an approved clinical use. Category 2 is the holding zone. a list of substances "under consideration" that compounding pharmacies could still work with while the FDA evaluated them. Being on Category 2 wasn't a green light exactly, but it provided a degree of legal tolerance that kept these compounds accessible through clinical channels.
When the FDA removed peptides including BPC-157, TB-500 (thymosin beta-4), and others from that list in recent years, it effectively closed that tolerance window. Compounding pharmacies can no longer legally prepare these substances for patient use, at least not without significant legal exposure. The compounds didn't get banned outright, but they lost the regulatory buffer that made them semi-legitimate.
This is a meaningful distinction. The FDA didn't classify these peptides as dangerous controlled substances. It simply withdrew the framework that allowed them to exist in a gray zone. For consumers, that gray zone was where most of the market lived.
The Supplement Market Was Already on Shaky Ground
Here's something that often gets buried in coverage of this issue: the vast majority of peptide supplements sold over the counter were never FDA approved to begin with. Unlike drugs, dietary supplements don't require premarket approval in the United States. Companies can sell peptide-labeled products without ever demonstrating to a regulator that those products are safe, effective, or even accurately labeled.
A 2022 analysis of commercially available peptide products found that a significant portion of tested samples did not match the peptide content listed on the label. Concentrations were off. Some products contained unrelated compounds. This isn't unique to peptides. It's a systemic issue in the supplement industry. But peptides carry particular risk because their biological activity depends heavily on molecular integrity, and oral bioavailability for many of them is limited or unproven.
The FDA's actions didn't create this problem. They exposed it. When compounding pharmacies were accessible as a regulated channel, there was at least some quality infrastructure in place. Now that channel is narrower, and the unregulated supplement market is absorbing the demand.
For performance-focused consumers who are serious about recovery and longevity, this matters a lot. If you're already paying attention to sleep quality and its downstream effects on hormones (as covered in our piece on how deep sleep builds muscle, burns fat, and supports brain health), layering in unverified peptide compounds without quality assurance works against that foundation, not with it.
Industry Lobbying Is Adding More Uncertainty
The supplement and compounding industries are not sitting still. Multiple trade organizations have been pushing the FDA to reconsider its removals, and there are active lobbying efforts to reclassify some of these peptides under alternative frameworks that would allow continued commercial availability. The International Peptide Society and compounding pharmacy advocacy groups have formally challenged several of the FDA's decisions.
Separately, some companies are attempting to market peptides as cosmetic ingredients or research compounds rather than dietary supplements, exploiting definitional gaps in federal law. You'll increasingly see products labeled "for research purposes only" or positioned as topical serums. These workarounds are legally ambiguous and, practically speaking, tell you very little about what's actually in the product.
Congressional pressure has also entered the picture. Legislators with constituencies in the compounding pharmacy industry have raised concerns about patient access, particularly for individuals using peptides under physician supervision for legitimate therapeutic purposes. Whether that pressure produces a legislative fix, a formal rulemaking process, or simply more delay is genuinely unclear at this point.
The takeaway: the regulatory situation is not resolved and probably won't be for several years. You're making decisions in real time without a stable framework to lean on.
Which Peptide Categories Are Most Affected
Not all peptides are in the same position. Here's how the landscape breaks down by category:
- Body protection and tissue repair peptides (BPC-157, TB-500): These are among the most affected. Both were removed from the Category 2 list and have no approved drug application in the US. They remain widely sold online, but purchasing them through retail channels puts you squarely outside any regulatory protection.
- Growth hormone secretagogues (sermorelin, ipamorelin, CJC-1295): Sermorelin has an approved drug form, which gives it more legal stability. Ipamorelin and CJC-1295 are in murkier territory. compounding pharmacies that continued offering them after the FDA's actions face increased scrutiny.
- Collagen peptides: These are the most commercially mainstream and the least affected by recent changes. Hydrolyzed collagen sold as a food ingredient operates under a different regulatory framework and doesn't fall into the bulk drug substance debate. Quality varies, but the legal landscape here is cleaner.
- Selank, Semax, and other nootropic peptides: These compounds are largely unscheduled in the US but also have no regulatory pathway. They've always existed in a research chemical zone. Nothing about the recent changes improves or worsens their status significantly, but quality control remains a serious concern.
How to Evaluate What's in Your Stack Right Now
If you're currently using peptide supplements, here are the questions you should be asking before your next order.
Is there a Certificate of Analysis (COA) from an independent lab? This is non-negotiable. A COA should confirm the identity and purity of the active compound, and it should come from a third-party lab that is not affiliated with the manufacturer. Ask for it. If a company won't provide one, that tells you everything you need to know.
Which third-party organizations have certified the product? Look for NSF International, Informed Sport, or USP verification. These programs require regular testing and create at least some accountability. Peptide supplements with these certifications are rare, but they exist. Their scarcity is itself informative.
How is the product being delivered? Oral bioavailability is a genuine issue for most peptides. If a company is selling an oral capsule of a peptide that has no established oral absorption data, that's a red flag for both efficacy and credibility. Injectable peptides raise their own concerns around sterility and sourcing. Be skeptical of confident claims in either direction.
Is a licensed healthcare provider involved in the recommendation? Physicians and registered dietitians who work in sports medicine and performance contexts stay current on this landscape. If your peptide use is being guided primarily by a subreddit or a fitness influencer's supplement code, reconsider that chain of information. This is the kind of situation where working with a qualified coach or practitioner. especially if you're navigating performance goals after your mid-30s. matters more than usual. The changes a coach should make first for athletes training after 35 include exactly this kind of risk-benefit recalibration.
What does the label actually say? Look at how the product is categorized. "Dietary supplement," "research chemical," and "for topical use only" each carry different regulatory implications and different levels of accountability. A product marketed as a research chemical is essentially telling you that no safety or efficacy claims apply.
The Bigger Picture on Supplement Accountability
The peptide situation is a sharp example of a broader dynamic in the supplement industry. Demand for performance compounds consistently outpaces regulatory infrastructure, and companies fill that gap with products that may or may not do what they claim. Consumers pay real money. sometimes $80 to $200 per month for premium peptide products. and carry real physiological risk, with very little institutional protection.
This isn't an argument against peptides categorically. The research on compounds like BPC-157 and certain secretagogues is genuinely interesting, and clinical use under physician supervision represents a different risk profile than buying unmarked powder online. But that nuance requires infrastructure that the current market often doesn't provide.
It's also worth keeping your performance goals in perspective. The evidence base for foundational behaviors. strength training, quality sleep, stress management, and sound nutrition. is orders of magnitude stronger than anything currently available for most peptides. Exercise is now officially recommended as a clinical intervention for heart health, a standard of evidence that no peptide supplement currently meets.
Similarly, the relationship between chronic stress, poor recovery, and systemic inflammation is well documented. Genetic research now shows how insomnia directly drives inflammation, a pathway that peptides are often marketed to address. but without the evidence rigor that would justify prioritizing them over sleep itself.
Use the regulatory uncertainty as a forcing function. Audit your stack, demand documentation, and talk to a qualified provider before adding or continuing any peptide compound. The market is going to stay messy for a while. Your approach to it doesn't have to be.